Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Cometriq (cabozantinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Metastatic Merkel Cell Carcinoma (MCC) and Medullary Thyroid Carcinoma (MTC): Cabozantinib effectively controlled MCC and MTC in an 83-year-old immunosuppressed male, with no MCC relapse after 24 months of treatment.
• Glucose and Lipid Metabolism in Thyroid Malignancies: Cabozantinib was associated with elevated glucose levels (prevalence: 1-17%), hypercholesterolemia (prevalence: 4-40%), and hypertriglyceridemia (prevalence: 1-86%).
• Renal Cell Carcinoma (RCC), Castration-Resistant Prostate Cancer (CRPC), Non-Small Cell Lung Cancer (NSCLC): Cabozantinib in combination therapy showed improved progression-free survival (PFS) compared to standard treatments.
• Radioiodine-Refractory Differentiated Thyroid Cancer (RAIR-DTC): Cabozantinib significantly improved PFS compared to placebo, though the effect size was not specified.
• Cabozantinib was associated with metabolic alterations, including elevated glucose levels and hyperlipidemia, potentially leading to severe, life-threatening events.
• Grade 3 or higher adverse events occurred in 48.5% of patients with medullary thyroid carcinoma (MTC) treated with TKIs, and 44.7% discontinued treatment due to these adverse events.
• Most patients with thyroid cancer experienced adverse effects, with substantial impact on the management of long-term outcomes.
• There is no population types or subgroups information available in the reviewed studies.